Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycium ruthenicum is a plant species commonly known as "black goji berry" or "black wolfberry." It is widely used in traditional Chinese medicine and as a dietary supplement. The fruit and its extracts are rich in anthocyanins and other polyphenols, conferring potent antioxidant and anti-inflammatory properties. Preclinical studies have shown that water extracts of Lycium ruthenicum can protect retinal ganglion cells from degeneration in mouse models of glaucoma by reducing oxidative stress and inhibiting microglial activation. Other reported pharmacological effects include potential benefits for cardiovascular disease, inflammation, fatigue, aging-related conditions, cardiac injury, experimental colitis, nonalcoholic fatty liver disease, and neuroprotection[1][3]. The mechanism of action appears to involve upregulation of antioxidant enzymes such as GPX-4 (glutathione peroxidase 4), Prdx-5 (peroxiredoxin 5), HO-1 (heme oxygenase 1), and SOD-2 (superoxide dismutase 2)[3]. Lycium ruthenicum is not a pharmaceutical drug but rather an herbal remedy or dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lycium ruthenicum.